- Home
- INKT vs ALGS Comparison
INKT vs ALGS Comparison
Compare INKT & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INKT | ALGS |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.6M | 49.7M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | INKT | ALGS |
|---|---|---|
| Price | $10.26 | $6.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $35.00 | ★ $46.67 |
| AVG Volume (30 Days) | 4.6K | ★ 34.9K |
| Earning Date | 03-23-2026 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,186,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.66 | $3.76 |
| 52 Week High | $76.00 | $13.69 |
Technical Indicators
Market Signals| Indicator | INKT | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 35.24 | 45.41 |
| Support Level | $6.85 | $6.92 |
| Resistance Level | $12.78 | $8.84 |
| Average True Range (ATR) | 0.36 | 0.56 |
| MACD | -0.04 | 0.06 |
| Stochastic Oscillator | 11.27 | 58.27 |
Price Performance
Historical ComparisonAbout INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.